{
 "PrintNo":"A10479","Session":2023,"Chamber":"ASSEMBLY","BillType":"Assembly","Published":"2024-05-29T14:47:25.0462Z",
 "Status":"IN_ASSEMBLY_COMM","Committee":"Health",
 "Milestones":[{"Type":"IN_ASSEMBLY_COMM","Date":"2024-05-29","Committee":"Health"}],
 "Actions":[{"Text":"REFERRED TO HEALTH","Date":"2024-05-29","Chamber":"ASSEMBLY"}],
 "Sponsors":[{"ID":1511,"Name":"Jake Ryan Blumencranz","Short":"BLUMENCRANZ"}],
 "Title":"Enacts the \"foreign drug transparency act\"",
 "Summary":"Enacts the \"foreign drug transparency act\"; requires the disclosure to a health plan, pharmacy and patient whether a prescription drug was manufactured or compounded in a foreign country; whether the prescription was approved by the federal food and drug administration foreign drug inspection program; requires the date of the last inspection of such prescription drug by the federal food and drug administration foreign drug inspection program; requires certain labelling on such drugs.",
 "LawSection":"Public Health Law","LawCode":"Amd ยง280-a, Pub Health L; amd ยง6810, Ed L",
 "ActClause":"AN ACT to amend the public health law and the education law, in relation to the labeling of prescriptions that are manufactured or compounded in a foreign country and subject to approval by the federal Food and Drug Administration foreign drug inspection program"
}